QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=47E0EEA2BC40E1BD863400E82B4EAF8C;jsessionid=D36E3125F3900EEA749DB406FB13DBE6;jsessionid=4F94692461D544307260E6B268950233;jsessionid=4805A4DC22BDE0A8E031BA057EAA47FE;jsessionid=C262276D8CE759105CFF10DCFD6EAD13;jsessionid=9A95FEAE12F9E15A166E225314A64215 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=47E0EEA2BC40E1BD863400E82B4EAF8C;jsessionid=D36E3125F3900EEA749DB406FB13DBE6;jsessionid=4F94692461D544307260E6B268950233;jsessionid=4805A4DC22BDE0A8E031BA057EAA47FE;jsessionid=C262276D8CE759105CFF10DCFD6EAD13;jsessionid=9A95FEAE12F9E15A166E225314A64215